Main active constituent identification in Guanxinjing capsule, a traditional Chinese medicine, for the treatment of coronary heart disease complicated with depression

Acta Pharmacologica Sinica

Volumn 39, Issue 6, 2018, Pages 975-987

  Zhang, Yan Qiong ^a   Guo, Qiu Yan ^a   Li, Qiu Yue ^a   Ren, Wei Qiong ^b   Tang, Shi Huan ^a   Wang, Song Song ^a   Liang, Ri Xin ^b   Li, De Feng ^a   Zhang, Yi ^a   Xu, Hai Yu ^a   Yang, Hong Jun ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b THE FIRST HOSPITAL OF HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

coronary heart disease; depression; Guanxinjing capsule; in silico ADME prediction; integrative pharmacology; network analysis; target prediction; traditional Chinese medicine

Indexed keywords

CARDIOVASCULAR AGENT; CHINESE DRUG; GUANXINJING CAPSULE; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ARTICLE; CHEMICAL COMPOSITION; CHINESE MEDICINE; COMPUTER MODEL; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MASS SPECTROMETRY; PRESCRIPTION; PROTEIN PROTEIN INTERACTION; THROMBOCYTE AGGREGATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BIOAVAILABILITY; COMPLICATION; CORONARY ARTERY DISEASE; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PROCEDURES; PROTEIN ANALYSIS; PSYCHOLOGY; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TREATMENT OUTCOME; ULTRAVIOLET SPECTROPHOTOMETRY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY DISEASE; DEPRESSION; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; PROTEIN INTERACTION MAPS; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

EID: 85048205178     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2017.117     Document Type: Article

References (49)

1. Nekouei ZK, Yousefy A, Doost HT, Manshaee G, Sadeghei M. Structural model of psychological risk and protective factors affecting on quality of life in patients with coronary heart disease: A psychocardiology model. J Res Med Sci 2014; 19: 90-8.
2. Meng Khoo C, Tai ES. Trends in the incidence and mortality of coronary heart disease in asian pacific region: The Singapore experience. J Atheroscler Thromb 2014; 21: S2-8.
3. Glozier N, Tofler GH, Colquhoun DM, Bunker SJ, Clarke DM, Hare DL, et al. Psychosocial risk factors for coronary heart disease. Med J Aust 2013; 199: 179-80.
4. Januzzi JL Jr, Stern TA, Pasternak RC, DeSanctis RW. The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med 2000; 160: 1913-21.
5. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006; 21: 30-8.
6. Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry 2003; 54: 241-7.
7. Colquhoun DM, Bunker SJ, Clarke DM, Glozier N, Hare DL, Hickie IB, et al. Screening, referral and treatment for depression in patients with coronary heart disease. Med J Aust 2013; 198: 483-4.
8. Francis DK, Bennett NR, Ferguson TS, Hennis AJ, Wilks RJ, Harris EN, et al. Disparities in cardiovascular disease among Caribbean populations: A systematic literature review. BMC Public Health 2015; 15: 828.
9. Fleischer T, Chang TT, Chiang JH, Hsieh CY, Sun MF, Yen HR. Integration of Chinese herbal medicine therapy improves survival of patients with chronic lymphocytic leukemia: A nationwide populationbased cohort study. Medicine (Baltimore) 2016; 95: E3788.
10. Liu J, Liu RL. The potential role of Chinese medicine in ameliorating extra-articular manifestations of rheumatoid arthritis. Chin J Integr Med 2011; 17: 735-7.
11. Wang AL, Chen Z, Luo J, Shang QH, Xu H. Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines. Chin J Integr Med 2016; 22: 56-66.
12. Li RP, Yu GH, Li JF, Tang SH. Discussion on relevant theories of "Qi-Blood-Shen" and formula implication of Guan-Xin-Jing capsule. Chin J Chin Metar Med 2016; 41: 4280-3.
13. National Pharmacopoeia Committee. Chinese pharmacopoeia. Part 1. Beijing: China Medical Science Press 2010: 3-361.
14. Song SJ, Wei FJ, Wei TY, Dong YJ. Clinical observation of Guanxinjing capsule in the treatment of qi deficiency and blood stasis type of coronary heart disease. China J Pharm Economics 2014, S1: 133-4.
15. Jiang JL, Li XJ. Clinical observation of Guanxinjing capsule in the treatment of coronary heart disease complicated with depression. Chin J Tradit Med Sci Technol 2014; 3: 316-7.
16. Yuan SG, Chen R. Mechanism of Guanxinjing capsule acting on psycho-cardiology. J New Chin Med 2013; 12: 176-8.
17. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 2007; 7: 16.
18. Lin CH, Chang TT, Sun MF, Chen HY, Tsai FJ, Chang KL, et al. Potent inhibitor design against H1N1 swine influenza: Structure-based and molecular dynamics analysis for M2 inhibitors from traditional Chinese medicine database. J Biomol Struct Dyn 2011; 28: 471-82.
19. Chen CY. TCM Database@Taiwan: The world's largest traditional Chinese medicine database for drug screening in silico. PLoS One 2011; 6: E15939.
20. Editorial: ChemSpider-a tool for Natural Products research. Nat Prod Rep 2015; 32: 1163-4.
21. Janicka M, Sztanke M, Sztanke K. Reversed-phase liquid chromatography with octadecylsilyl, immobilized artificial membrane and cholesterol columns in correlation studies with in silico biological descriptors of newly synthesized antiproliferative and analgesic active constituents. J Chromatogr A 2013; 1318: 92-101.
22. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-6.
23. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 2005; 33: D514-7.
24. Chen JY, Mamidipalli S, Huan T. HAPPI: An online database of comprehensive human annotated and predicted protein interactions. BMC Genomics 2009; 10: S16.
25. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 2009; 37: D619-22.
26. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics 2005; 21: 2076-82.
27. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, Derow C, et al. The IntAct molecular interaction database in 2010. Nucleic Acids Res 2010; 38: D525-31.
28. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human Protein Reference Database-2009 update. Nucleic Acids Res 2009; 37: D767-72.
29. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, Perfetto L, et al. MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 2010; 38: D532-9.
30. Lehne B, Schlitt T. Protein-protein interaction databases: Keeping up with growing interactomes. Hum Genomics 2009; 3: 291-7.
31. Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H. PDZBase: A protein-protein interaction database for PDZ-domains. Bioinformatics 2005; 21: 827-8.
32. Guo Q, Zhong M, Xu H, Mao X, Zhang Y, Lin N. A systems biology perspective on the molecular mechanisms underlying the therapeutic effects of Buyang Huanwu Decoction on ischemic stroke. Rejuvenation Res 2015; 18: 313-25.
33. Zhang Y, Guo X, Wang D, Li R, Li X, Xu Y, et al. A systems biologybased investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Sci Rep 2014; 4: 4154.
34. Zhang Y, Wang D, Tan S, Xu H, Liu C, Lin N. A systems biology-based investigation into the pharmacological mechanisms of Wu Tou Tang acting on rheumatoid arthritis by integrating network analysis. Evid Based Complement Alternat Med 2013; 2013: 548498.
35. Wixon J, Kell D. The Kyoto encyclopedia of genes and genomes-KEGG. Yeast 2000; 17: 48-55.
36. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: 3.
37. Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, Wang YY. Understanding ZHENG in traditional Chinese medicine in the context of neuroendocrine-immune network. IET Syst Biol 2007; 1: 51-60.
38. Zhang Y, Xu H, Chen X, Chen C, Wang H, Meng F, et al. Simultaneous quantification of 17 constituents from Yuanhu Zhitong tablet using rapid resolution liquid chromatography coupled with a triple quadrupole electrospray tandem mass spectrometry. J Pharm Biomed Anal 2011; 56: 497-504.
39. Wang S, Xu H, Ma Y, Wang X, Shi Y, Huang B, et al. Characterization and rapid identification of chemical constituents of NaoXinTong capsules by UHPLC-linear ion trap/Orbitrap mass spectrometry. J Pharm Biomed Anal 2015; 111: 104-18.
40. Tao Y, Xu H, Wang S, Wang B, Zhang Y, Wang W, et al. Identification of the absorbed constituents after oral administration of Yuanhu Zhitong prescription extract and its pharmacokinetic study by rapid resolution liquid chromatography/quadrupole time-of-flight. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 935: 1-9.
41. Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight constituents. Pharm Res 1998; 15: 1490-4.
42. Xu H, Shi Y, Zhang Y, Jia Q, Li D, Zhang Y, et al. Identification of key active constituents of Buchang Naoxintong capsules with therapeutic effects against ischemic stroke by using an integrative pharmacologybased approach. Mol Biosyst 2016; 12: 233-45.
43. Harrington MA, Shaw K, Zhong P, Ciaranello RD. Agonist-induced desensitization and loss of high-affinity binding sites of stably expressed human 5-HT1A receptors. J Pharmacol Exp 1994; 268: 1098-106.
44. Hofmann Bowman MA, McNally EM. Genetic pathways of vascular calcification. Trends Cardiovasc Med 2012; 22: 93-8.
45. Henttonen AT, Kortelainen ML, Kunnas TA, Nikkari ST. Estrogen receptor-1 genotype is related to coronary intima thickness in young to middle-aged women. Scand J Clin Lab Invest 2007; 67: 380-6.
46. Vital SA, Becker F, Holloway PM, Russell J, Perretti M, Granger DN, et al. Formyl-peptide receptor 2/3/Lipoxin A4 receptor regulates neutrophil-platelet aggregation and attenuates cerebral inflammation: Impact for therapy in cardiovascular disease. Circulation 2016; 133: 2169-79.
47. Bullock-Palmer RP. Prevention, detection and management of coronary artery disease in minority females. Ethn Dis 2015; 25: 499-506.
48. Kessler T, Vilne B, Schunkert H. The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med 2016; 8: 688-701.
49. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-75.